Roxadustat
Phase 2Completed 1 views this week 0 watching💤 Quiet
Interest: 35/100
35
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Chemotherapy Induced Anemia
Conditions
Chemotherapy Induced Anemia
Trial Timeline
Aug 20, 2019 → Apr 23, 2021
NCT ID
NCT04076943About Roxadustat
Roxadustat is a phase 2 stage product being developed by Astellas Pharma for Chemotherapy Induced Anemia. The current trial status is completed. This product is registered under clinical trial identifier NCT04076943. Target conditions include Chemotherapy Induced Anemia.
What happened to similar drugs?
3 of 20 similar drugs in Chemotherapy Induced Anemia were approved
Approved (3) Terminated (4) Active (14)
🔄recombinant human erythropoietin + recombinant human erythropoietin placeboChugai PharmaceuticalPhase 3
🔄olanzapine plus fosaprepitant-based triple regimen + placebo plus fosaprepitant-based triple regimenSun PharmaceuticalPhase 3
Hype Score Breakdown
Clinical
12
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (12)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05970172 | Phase 3 | Recruiting |
| NCT04408820 | Pre-clinical | Completed |
| NCT04076943 | Phase 2 | Completed |
| NCT03960489 | Phase 1 | Completed |
| NCT02964936 | Phase 3 | Completed |
| NCT02965040 | Phase 1 | Completed |
| NCT02780726 | Phase 3 | Completed |
| NCT02780141 | Phase 3 | Completed |
| NCT02779764 | Phase 3 | Completed |
| NCT01630889 | Phase 2 | Completed |
| NCT01244763 | Phase 2 | Completed |
| NCT01083888 | Phase 1 | Completed |
Competing Products
20 competing products in Chemotherapy Induced Anemia